News & Events
-
December 21, 2017
Qualitative Development and Content Validity of the Non–Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-Reported Outcome Instrument
McCarrier K, Abraham L, Blum S, Bush E, Bushnell D, Carpenter L, Coons S, Houle C, Martin M, Mathews M, Trivedi M, Thase M, on behalf of the PRO Consortium Depression Working Group. Qualitative Development and Cognitive Evaluation of the Symptoms of Major Depressive Disorder (S-MDD), A Consortium-Developed Patient Reported Outcome Measure. 53rd New Clinical Drug Evaluation Unit (NCDEU): An Annual Meeting Sponsored by the American Society of Clinical Psychopharmacology (ASCP); 2013 May 28; Hollywood, FL, USA.
-
December 18, 2017
C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)
Tucson, AZ – December 18, 2017 Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA) for the Symptoms of Major Depressive Disorder Scale (SMDDS). This qualification of the SMDDS for exploratory use represents a major milestone for the PRO... - December 8, 2017
- December 8, 2017
-
December 4, 2017
C-Path and FARA announce collaborative data aggregation project for Friedreich’s ataxia
Tucson, AZ, and Downingtown, PA — December 4, 2017 — Critical Path Institute‘s (C-Path) Data Collaboration Center (DCC) and the Friedreich’s Ataxia Research Alliance (FARA) have announced that they will work together to develop an aggregated database of clinical data for Friedreich’s ataxia (FA). Use of this database will promote collaborative research to...
